

(51) International Patent Classification:
A01N 43/42 (2006.01)(21) International Application Number:
PCT/US2012/024746(22) International Filing Date:
10 February 2012 (10.02.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/441,902	11 February 2011 (11.02.2011)	US
61/530,905	18 October 2011 (18.10.2011)	US
61/556,649	7 November 2011 (07.11.2011)	US
61/583,024	4 January 2012 (04.01.2012)	US

(71) Applicant (for all designated States except US): **SALIX PHARMACEUTICALS, LTD.** [US/US]; 8510 Colonnade Center Drive, Raleigh, NC 27615 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **PARENT, Stephan** [US/US]; 2120 Cumulus Ct, West Lafayette, IN 47906 (US). **McQUEEN, Lisa** [US/US]; 3472 Tunbridge Way, West Lafayette, IN 47906 (US). **ANDRES, Patricia** [US/US]; 2307 Sycamore Lane, West Lafayette, IN 47906(US). **SCHIELDS, Paul** [US/US]; 4203 Peterborough, West Lafayette, IN 47906 (US). **WU, Yiduo** [CN/US]; 947B Village Drive East, North Brunswick, NJ 08902 (US). **DING, Fei** [US/US]; 7575 West 106th Street, Apartment 370, Overland Park, KS 66212 (US). **SMIT, Jared P.** [US/US]; 4509 McCarty Lane, Lafayette, Indiana 47905 (US).(74) Agents: **SPARKS, Jonathan, M.** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU,

[Continued on next page]

(54) Title: FORMS OF RIFAXIMIN AND USES THEREOF

Figure 1. Representative XRPD patterns of rifaximin Form μ .

(57) Abstract: Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.



TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:
20 February 2014

(15) Information about Correction:

Previous Correction:
see Notice of 22 November 2012

Published:

— *with international search report (Art. 21(3))*